IL17A and psoriasis vulgaris: Considering apremilast’s role in reducing IL-17F, IL-17A, IL-22, and TNF-α plasma levels in patients with moderate to severe plaque psoriasis, it could be hypothesized that apremilast acts as a pleiotropic molecule, blocking a common pathway shared by both PsO and MetS.